Technology, Patient Centricity and Disruption Remain Top of Mind for Health System Execs

Posted by Pratap Khedkar on Thu, May 02, 2019

I recently joined more than 4,000 attendees at the Becker's Hospital Review 10th Annual Meeting, held in Chicago in early April, to learn about the most pressing issues in the hospital and health system arena from a deep bench of industry experts. Interesting insights emerged across three of the critical themes that the healthcare industry is contending with, which got me thinking:


>
Read More

Ramping Up Real-World Evidence: Assessing the FDA’s New RWE Framework

Posted by Qin Ye on Thu, Jan 24, 2019

Ishita Srivastava and Divya Babbar co-authored this blog post with Qin Ye.

The FDA considers the use of real-world data and real-world evidence a top strategic priority, and on Dec. 6, it unveiled its much-anticipated RWE framework to support the development of drugs and biologics. The framework is aimed at evaluating the potential use of RWE for assessing a product’s effectiveness and focuses on increased stakeholder engagement to effectively leverage RWD and RWE for public health purposes.


>
Read More

Walking the Walk: How Pharma Companies Can Deliver Patient-Centric Experiences

Posted by Hensley Evans on Thu, Jul 12, 2018

The pharmaceutical industry has been talking about patient centricity for a long time, but despite having been a topic of great interest for more than a decade, there remains a lot of uncertainty about what being a truly patient-centric organization means. What does it mean to walk the walk and, more importantly, how can organizations ensure that a focus on patient centricity not only benefits patients but also drives business success?


>
Read More

Five Steps to Address the Pain Points of Co-Pay Accumulator Programs

Posted by Howard Deutsch on Wed, Jan 31, 2018

In the cat-and-mouse co-pay card game, payers have made their next move. Pharmacy benefit managers have been promoting “co-pay accumulator” programs to plan sponsors as a way to reduce specialty drug spending. Left alone, these programs will result in confused patients who are less likely to adhere to their medications, and high costs for pharmaceutical manufacturers. Pharma companies need to respond.


>
Read More

As the Goalposts Keep Moving, Pharma Can Help Providers Continue to Move the Ball Forward

Posted by Paul Darling on Mon, Nov 20, 2017

As stakeholders throughout the healthcare ecosystem continue to transition from a fee-for-service model toward value-based care—and as providers try to keep up while feeling increasingly burdened by paperwork and disconnected from patients—the Centers for Medicare & Medicaid Services (CMS) keeps moving the goalposts.


>
Read More